Cibus, Inc. (CBUS) is a San Diego–based agricultural biotechnology company that makes precise edits to a seed company's own elite crop varieties — with no foreign DNA added — and licenses those improved traits back to the customer for royalties. Its pipeline centres on herbicide-tolerant rice, pod shatter reduction in canola and oilseed rape, and a biofragrance ingredient business built on yeast fermentation.
In midday trading Thursday, the stock changed hands at $1.22, down $0.15, or 10.95%, from the prior session's close of $1.37. The direction is unambiguously lower, and the move erases the gains from a sharp two-day advance that lifted shares from $1.20 on November 16 to $1.39 on November 17. No company-specific announcement explained the session's decline; the drivers were a still-unresolved funding question and the unwind of speculative positioning built during that rally.
The third quarter, reported after the close on November 12, delivered revenue of $0.8 million against expectations near $2.0 million, and a per-share loss of $0.29 versus a consensus loss of about $0.27. More consequentially, cash and equivalents stood at $10.7 million at September 30, down from $30.3 million at the start of the year, with management stating that current resources fund operations only into early first quarter of 2027 absent new capital.
Cost discipline has improved — research and development expense fell to $7.9 million from $10.8 million, and nine-month operating cash use dropped roughly 19% — but the royalty liability now stands at $263.4 million and stockholders' equity has turned negative. For a pre-revenue-royalty company trading under $1.50, the timing and terms of the next raise carry disproportionate weight, and the equity historically sells off when that overhang returns to the foreground.
The November 17 session, which carried the stock 15.8% higher on roughly 472,000 shares — several times the recent daily turnover of roughly 70,000 to 80,000 shares — was not accompanied by a company release or filing. Without a durable catalyst, that kind of volume spike in a sub-$2 micro-cap tends to be short-lived, and the subsequent two sessions have retraced the entire advance. That pattern is consistent with momentum-driven buying reversing into profit-taking rather than with a fresh deterioration in fundamentals.
Sell-side sentiment reset lower after the quarter. One covering firm cut its price target to $9 from $16 while maintaining a Buy rating, noting that the crop-trait royalty ramp is now a 2028 event and that continued cash burn adds financing risk. A target cut of that magnitude does not by itself move a stock on any given day, but it reframes the timeline investors are underwriting and removes the expectation of near-term royalty revenue from Latin America.
The decline is company-specific rather than sector-driven. Cibus trades as a thin, heavily retail-influenced micro-cap with a market capitalisation of roughly $93 million on about 77 million shares, and its daily swings are driven far more by liquidity and positioning than by agricultural biotechnology peers. Turnover on Thursday was light relative to the November 17 spike, which suggests limited buying interest rather than aggressive institutional selling.
Technically, the stock failed to hold above the $1.35–$1.40 area that capped it in late November and has slipped back to the $1.20 level that marked the base of the mid-month rally. The November 13 low of $1.02 remains the nearest reference point on the downside, while the $1.50–$1.52 intraday high from November 17 is the immediate resistance level.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Cibus scores 44 out of 100.
The verified fundamental news is moderate but material for a company this size: a 41% revenue miss, a cash position that funds only about one more quarter, and a halved price target. The price move was roughly 3.3 times the stock's typical absolute daily change of 3.3% over the past 60 sessions, and only one of those sessions produced a move this large — the 15.8% gain on November 17. Strong-but-not-transformative news combined with an unusual move produces the mid-range score.
The most immediate variable is financing. Management has acknowledged an acute need for near-term capital, so the size, structure, and pricing of any raise will shape the next leg of trading. Beyond that, investors await a definitive commercialization agreement with Interoc covering herbicide-tolerant rice, with field results from Interoc's own varieties in Ecuador expected in the first quarter of 2027, and a regulatory dossier for Brazil in preparation.
On the ingredients side, the partner has approved the first two biofragrance products and manufacturing scale-up has begun, but purchase orders depend on formulation wins that have not yet materialised. Fourth-quarter and full-year 2026 results, expected in March, will be scrutinised for cash burn against the roughly $35 million annualised exit target. Risks include further equity dilution, commercial launch slippage beyond 2028, and pending regulatory approvals in Latin America and Europe.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. Bots vary widely by strategy, timeframe, performance metrics, and traded symbols, so the selection is designed to surface the strategies currently working rather than the ones that worked last quarter. For readers tracking volatile micro-caps like this one, it is a practical starting point for comparing systematic approaches.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The RSI Indicator for CBUS moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 37 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where CBUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on CBUS as a result. In 71 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CBUS just turned positive on November 16, 2026. Looking at past instances where CBUS's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Following a +23.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBUS advanced for three days, in 206 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CBUS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CBUS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. CBUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.093) is normal, around the industry mean (3.596). P/E Ratio (-0.781) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (21.692) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology